Pressure BioSciences, Inc. (PBIO) Game-Changing Pressure Cycling Technology Is Revolutionizing Scientific Research at the Most Fundamental Level
- Company is positioned to disrupt the $6 billion global life sciences sample preparation market
- Pressure Cycling Technology (PCT) is a game-changer in bolstering the quality and efficacy of scientific research
- Next generation Barocycler 2320EXTREME instrument is becoming a crucial research tool in “Cancer Moonshot” laboratories and has been named a finalist in the prestigious 2017 R&D 100 Awards (the “Oscars of Innovation”)
The first steps in any process are some of the most crucial, as the earliest steps along a path often direct the entire course of a journey. Similarly, the beginnings of any scientific endeavor influence all other aspects going forward. Understanding this fundamental truth, Pressure BioSciences, Inc. (OTCQB: PBIO) is revolutionizing scientific research from the very earliest steps (i.e., sample preparation).
Serving the $6 billion life sciences sample preparation market, PBIO offers a game-changing product line that can control the critical sample preparation process in an unprecedented way, enabling researchers to start their experimentation with samples of unmatched quality. In any type of scientific research, the quality of the sample one begins with hugely affects the efficacy, outcome and importance of the research. The ability to reproducibly create high quality samples for testing and research is unquestionably impactful and has applications in a wide variety of scientific research and discovery areas.
PBIO’s product line is based on a patented, enabling technology platform called pressure cycling technology (PCT), which employs alternating cycles of hydrostatic pressure—ranging between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi)—to safely and reproducibly control critical biological processes. For example, one of these processes is lysis, or the breakage of cells.
Traditionally, when cells are ruptured for study, they must be broken open using chemicals, blades, metal beads, sound waves or other inadequate methods that can damage and alter the invaluable biomolecules inside the cells they are breaking (e.g., DNA, proteins and lipids), thereby negatively impacting the efficacy of the research performed using the biomolecules. With PBIO’s pioneering PCT technology, however, the lysis process is controlled like never before. Customized, controlled cycles of hydrostatic (water) pressure are used to rupture the cells in a controlled manner, inside a very safe pressure chamber. The pressure is exquisitely controlled and customized to an exact level of PSI, according to the type of cells being broken, enabling the optimum amount of pressure to be delivered to rupture the cell in an ideal and reproducible way (e.g., not too much pressure and not too little) —something that has never before been accomplished in a commercial setting.
The potential impact of this innovative method is astronomical, enabling the creation of truer, more legitimate samples for analysis, which allows research scientists to commence their studies with biological samples of unmatched integrity. The resulting impact on the efficacy and outcomes of scientific research is potentially enormous.
Through PCT, pathogens like viruses and bacteria can further be inactivated through the use of hydrostatic pressure, which makes such samples far safer to study. This is yet another PBIO innovation with astounding potential applications in a wide variety of markets.
The lead product in the PBIO line is the newly released, next-generation Barocycler 2320EXTREME instrument, which has been named a finalist in the prestigious 2017 R&D 100 Awards (also known as the “Oscars of Innovation”). This exciting instrument is being hailed as an essential component of the United States’ $1.8 billion “Cancer Moonshot” program by a number of Moonshot researchers. Professor Phil Robinson, co-head of the Children’s Medical Research Institute cancer research center (Sydney, Australia) and the first international Cancer Moonshot collaborator, recently stated, “Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”
PBIO markets its pioneering PCT-based instruments throughout the U.S., Canada, Europe, Australia, Japan and China. The chief applications of PCT technology are in biomarker discovery, forensics, agriculture and pathology (preparation of tissue biopsy samples for analysis). This wave-making technology is also being applied in the specialized fields of drug discovery and design, biotherapeutics characterization, soil and plant biology, vaccine development and histology.
For further information about Pressure BioSciences, the company’s PCT technology and various other innovative offerings, visit the company’s website at www.PressureBioSciences.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company is positioned to disrupt the $6 billion global life sciences sample preparation market
- Pressure Cycling Technology (PCT) is a game-changer in bolstering the quality and efficacy of scientific research
- Next generation Barocycler 2320EXTREME instrument is becoming a crucial research tool in “Cancer Moonshot” laboratories and has been named a finalist in the prestigious 2017 R&D 100 Awards (the “Oscars of Innovation”)
The first steps in any process are some of the most crucial, as the earliest steps along a path often direct the entire course of a journey. Similarly, the beginnings of any scientific endeavor influence all other aspects going forward. Understanding this fundamental truth, Pressure BioSciences, Inc. (OTCQB: PBIO) is revolutionizing scientific research from the very earliest steps (i.e., sample preparation).
Serving the $6 billion life sciences sample preparation market, PBIO offers a game-changing product line that can control the critical sample preparation process in an unprecedented way, enabling researchers to start their experimentation with samples of unmatched quality. In any type of scientific research, the quality of the sample one begins with hugely affects the efficacy, outcome and importance of the research. The ability to reproducibly create high quality samples for testing and research is unquestionably impactful and has applications in a wide variety of scientific research and discovery areas.
PBIO’s product line is based on a patented, enabling technology platform called pressure cycling technology (PCT), which employs alternating cycles of hydrostatic pressure—ranging between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi)—to safely and reproducibly control critical biological processes. For example, one of these processes is lysis, or the breakage of cells.
Traditionally, when cells are ruptured for study, they must be broken open using chemicals, blades, metal beads, sound waves or other inadequate methods that can damage and alter the invaluable biomolecules inside the cells they are breaking (e.g., DNA, proteins and lipids), thereby negatively impacting the efficacy of the research performed using the biomolecules. With PBIO’s pioneering PCT technology, however, the lysis process is controlled like never before. Customized, controlled cycles of hydrostatic (water) pressure are used to rupture the cells in a controlled manner, inside a very safe pressure chamber. The pressure is exquisitely controlled and customized to an exact level of PSI, according to the type of cells being broken, enabling the optimum amount of pressure to be delivered to rupture the cell in an ideal and reproducible way (e.g., not too much pressure and not too little) —something that has never before been accomplished in a commercial setting.
The potential impact of this innovative method is astronomical, enabling the creation of truer, more legitimate samples for analysis, which allows research scientists to commence their studies with biological samples of unmatched integrity. The resulting impact on the efficacy and outcomes of scientific research is potentially enormous.
Through PCT, pathogens like viruses and bacteria can further be inactivated through the use of hydrostatic pressure, which makes such samples far safer to study. This is yet another PBIO innovation with astounding potential applications in a wide variety of markets.
The lead product in the PBIO line is the newly released, next-generation Barocycler 2320EXTREME instrument, which has been named a finalist in the prestigious 2017 R&D 100 Awards (also known as the “Oscars of Innovation”). This exciting instrument is being hailed as an essential component of the United States’ $1.8 billion “Cancer Moonshot” program by a number of Moonshot researchers. Professor Phil Robinson, co-head of the Children’s Medical Research Institute cancer research center (Sydney, Australia) and the first international Cancer Moonshot collaborator, recently stated, “Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”
PBIO markets its pioneering PCT-based instruments throughout the U.S., Canada, Europe, Australia, Japan and China. The chief applications of PCT technology are in biomarker discovery, forensics, agriculture and pathology (preparation of tissue biopsy samples for analysis). This wave-making technology is also being applied in the specialized fields of drug discovery and design, biotherapeutics characterization, soil and plant biology, vaccine development and histology.
For further information about Pressure BioSciences, the company’s PCT technology and various other innovative offerings, visit the company’s website at www.PressureBioSciences.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
